-+ 0.00%
-+ 0.00%
-+ 0.00%

After the US Food and Drug Administration declined to approve Coptic Therapeutics's drugs to treat rare hormone disorders, the company's stock price fell 34.5% in pre-market trading.

Zhitongcaijing·12/31/2025 13:33:16
Listen to the news
After the US Food and Drug Administration declined to approve Coptic Therapeutics's drugs to treat rare hormone disorders, the company's stock price fell 34.5% in pre-market trading.